FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Am J Reprod Immunol / Evidence for anti-inflammatory effects of firocoxib administ...
American journal of reproductive immunology (New York, N.Y. : 1989)2021; 86(1); e13396; doi: 10.1111/aji.13396

Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis.

Abstract: Minimal evidence exists supporting therapeutic selections for equine placentitis. The goal of this study was to characterize the anti-inflammatory effects of firocoxib when administered to mares with placentitis. Mares (gestation D270-300) were assigned to: INFECT (n = 6; placentitis, no treatment), FIRO (n = 6; placentitis, firocoxib, 0.1 mg/kg, PO, daily), and NORM (n = 6; no infection/treatment). Allantoic fluid (8 hours, 24 hours, birth) and amniotic fluid (birth) were collected from mares after infection. Concentrations of IL-1β, IL-6, TNF-α, IL-10, PGF , and PGE in fluids were measured by ELISA. mRNA expression of IL-1β, IL-6, TNF-α, IL-8, IL-10, matrix metalloproteinases (MMPs) -1, 3, and 9 in fetal membranes/fetuses was quantified using real-time PCR. Allantoic TNF-α concentrations were lowest in FIRO at 8 hours and 24 hours post-infection; IL-6 concentrations were lower in FIRO than NORM at 8 hours, lower in FIRO than INFECT at 24 hours post-inoculation, and lower in NORM than FIRO or INFECT at birth. Marginal mean allantoic IL-β and IL-10 concentrations were lower in FIRO and NORM than INFECT. Amniotic fluid cytokines were lowest in NORM with all measurements in that group being below the limit of detection. Allantoic PGF concentrations were lower in FIRO and INFECT than NORM at 8 hours post-inoculation, and lower in FIRO than INFECT or NORM at 24 hours post-inoculation. Allantoic PGE concentrations were lower in FIRO than INFECT. Amniotic PGF and PGE concentrations were lower in NORM than INFECT. In fetal membranes, group differences with respect to IL-1β, IL-6, IL-8, and MMP1 were dependent on tissue type. Data suggest a suppressive effect of firocoxib administration on cytokine and prostaglandin production in mares with placentitis.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2021-02-10 PubMed ID: 33569862DOI: 10.1111/aji.13396Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper focuses on investigating the anti-inflammatory effects of firocoxib, a veterinary drug, on horses (mares) with experimentally induced placentitis, a condition of inflamed placenta. The study underscores the lack of existing evidence to guide therapy decisions for equine placentitis, aiming to fill that research gap.

Objectives and Methods

  • The primary objective of the research was to assess the effectiveness of firocoxib in reducing inflammation among mares with placentitis.
  • The study involved grouping mares (around 270-300 days into pregnancy) into three categories for studying different scenarios: those with untreated placentitis (INFECT), those with placentitis treated with firocoxib (FIRO), and healthy control mares without infection or treatment (NORM).
  • Data for the research was extracted from allantoic fluid, collected 8 hours, 24 hours, and at birth after infection, and amniotic fluid obtained at birth.
  • Concentrations of particular substances, including IL-1β, IL-6, TNF-α, IL-10, PGF, and PGE, known markers of inflammation, were measured using the ELISA technique. Also, the mRNA expression of these substances, along with matrix metalloproteinases (MMPs) -1, 3, and 9 in fetal membranes and fetuses was quantified using real-time PCR, a technique to amplify and measure DNA.

Key Findings

  • Allantoic TNF-α concentrations were lowest in the FIRO group 8 hours and 24 hours post-infection when compared with the INFECT group.
  • IL-6 concentrations, key indicators of inflammation, were comparably lower in the firocoxib-treated group (FIRO) compared to the other groups at different time intervals post-infection.
  • The cytokine levels in the amniotic fluid were lowest in the NORM group with all measurements being below the limit of detection, expectedly in line with the non-infected and untreated nature of the group.
  • PGF and PGE concentrations, involved in the inflammatory response, followed a similar trend, with lower levels in the FIRO group compared to the INFECT group. In the INFECT group, these concentrations were higher than in the NORM group.
  • The research also underscores that differences in the levels of IL-1β, IL-6, IL-8, and MMP1 in fetal membranes varied depending on the tissue type.

Conclusion

  • Overall, the study concludes that firocoxib shows a suppressive effect on cytokine and prostaglandin – key markers of inflammation – production in mares with placentitis, thereby indicating its potential effectiveness as an anti-inflammatory therapeutic option for equine placentitis.

Cite This Article

APA
Macpherson ML, Giguère S, Pozor MA, Burden CA, Berghaus LJ, Berghaus RD, Varner JC, Hayna JT, Benson SM, Randell SA, Lyle SK, Kelleman AA, Hart KA, Mallicote MF, Horohov DW. (2021). Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis. Am J Reprod Immunol, 86(1), e13396. https://doi.org/10.1111/aji.13396

Publication

American journal of reproductive immunology (New York, N.Y. : 1989)
ISSN: 1600-0897
NlmUniqueID: 8912860
Country: Denmark
Language: English
Volume: 86
Issue: 1
Pages: e13396

Researcher Affiliations

Macpherson, Margo L
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Giguère, Steeve
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Pozor, Malgorzata A
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Burden, Chelsie A
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Berghaus, Londa J
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Berghaus, Roy D
  • Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Varner, Jennifer C
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Hayna, Justin T
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Benson, Susanne M
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Randell, Sarah A
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Lyle, Sara K
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
Kelleman, Audrey A
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Hart, Kelsey A
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Mallicote, Martha F
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
Horohov, David W
  • Department of Veterinary Science, Gluck Equine Research Center, University of Kentucky, Lexington, KY, USA.

MeSH Terms

  • 4-Butyrolactone / analogs & derivatives
  • 4-Butyrolactone / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Female
  • Horse Diseases / drug therapy
  • Horses
  • Inflammation / drug therapy
  • Interleukin-6 / metabolism
  • Matrix Metalloproteinase 1 / metabolism
  • Placenta / metabolism
  • Placenta / pathology
  • Placenta Diseases / drug therapy
  • Pregnancy
  • Prostaglandins / metabolism
  • Sulfones / therapeutic use
  • Tumor Necrosis Factor-alpha / metabolism

References

This article includes 54 references
  1. Giles RC, Donahue JM, Hong CB. Causes of abortion, stillbirth, and perinatal death in horses - 3,527 cases (1986-1991). J Am Vet Med Assoc 1993;203(8):1170-1175.
  2. Hong CB, Donahue JM, Giles RC. Etiology and pathology of equine placentitis. J Vet Diagn Invest 1993;5(1):56-63.
  3. Laugier C, Foucher N, Sevin C, Leon A, Tapprest J. A 24-year retrospective study of equine abortion in Normandy (France). J Equine Vet Sci 2011;31(3):116-123.
    doi: 10.1016/j.jevs.2010.12.012google scholar: lookup
  4. Platt H. Infection of the horse fetus. J Reprod Fert Suppl 1975;23:605-610.
  5. Simmons LE, Rubens CE, Darmstadt GL, Gravett MG. Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes, and interventions. Semin Perinatol 2010;34(6):408-415.
    doi: 10.1053/j.semperi.2010.09.005google scholar: lookup
  6. Adams Waldorf KM, Rubens CE, Gravett MG. Use of nonhuman primate models to investigate mechanisms of infection-associated preterm birth. BJOG Int J Obstet Gynaecol 2011;118(2):136-144.
    doi: 10.1111/j.1471-0528.2010.02728.xgoogle scholar: lookup
  7. Hendry JM, Lester GD, Hansen PJ. Patterns of uterine myoelectrical activity in reproductively normal mares in late gestation and in mares with experimentally induced ascending placentitis. Theriogenology 2002;58(2-4):853-855.
  8. Mays MBC, Leblanc MM, Paccamonti D. Route of fetal infection in a model of ascending placentitis. Theriogenology 2002;58(2-4):791-792.
  9. LeBlanc MM, Giguere S, Brauer K. Premature delivery in ascending placentitis is associated with increased expression of placental cytokines and allantoic fluid prostaglandins E-2 and F-2 alpha. Theriogenology 2002;58(2-4):841-844.
  10. Stawicki RJ, Ruebel H, Hansen PJ. Endocrinological findings in an experimental model of ascending placentitis in the mare. Theriogenology 2002;58(2-4):849-852.
  11. Fedorka CE, Ball BA, Scoggin KE, Loux SC, Troedsson MHT, Adams AA. The feto-maternal immune response to equine placentitis. Am J Reprod Immunol 2019;82(5):e13179.
    doi: 10.1111/aji.13179google scholar: lookup
  12. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science 2014;345(6198):760-765.
    doi: 10.1126/science.1251816google scholar: lookup
  13. Gravett MG, Adams KM, Sadowsky DW. Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model. Am J Obstet Gynecol 2007;197(5):518-518.
  14. Bailey CS, Macpherson ML, Pozor MA. Treatment efficacy of trimethoprim sulfamethoxazole, pentoxifylline and altrenogest in experimentally induced equine placentitis. Theriogenology 2010;74(3):402-412.
    doi: 10.1016/j.theriogenology.2010.02.023google scholar: lookup
  15. Rebello SA, Macpherson ML, Murchie TA, Leblanc MM, Vickroy TW. Placental transfer of trimethoprim sulfamethoxazole and pentoxifylline in pony mares. Anim Reprod Sci 2006;94(1-4):432-433.
  16. Murchie TA, Macpherson ML, LeBlanc MM, Luznar S, Vickroy TW. Continuous monitoring of penicillin G and gentamicin in allantoic fluid of pregnant pony mares by in vivo microdialysis. Equine Vet J 2006;38(6):520-525.
    doi: 10.2746/042516406x156136google scholar: lookup
  17. Graczyk J, Macpherson ML, Pozor MA. Treatment efficacy of trimethoprim sulfamethoxazole and pentoxifylline in equine placentitis. Anim Reprod Sci 2006;94(1-4):434-435.
  18. Christiansen DL, Moulton K, Walters FK, Cooley AJ, LeBlanc M, Ryan P. Evidenced-based medicine approach to develop efficacious therapies for late-gestation mares presenting with uterine infections using an experimentally-induced placentitis model. Anim Reprod Sci 2010;121(1-2, Supplement 1):345-346.
  19. Bailey CS, Macpherson ML, Graczyk J. Treatment efficacy of trimethoprim sulfamethoxazole, pentoxifylline, and altrenogest in equine placentitis. Theriogenology 2007;68(3):516-517.
  20. Orsini JA, Ryan WG, Carithers DS, Boston RC. Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses. Am J Vet Res 2012;73(5):664-671.
  21. Davila D, Keeshen TP, Evans RB, Conzemius MG. Comparison of the analgesic efficacy of perioperative firocoxib and tramadol administration in dogs undergoing tibial plateau leveling osteotomy. J Am Vet Med Assoc 2013;243(2):225-231.
  22. Knych HK. Nonsteroidal anti-inflammatory drug use in horses. Vet Clin North Am Equine Practice 2017;33(1):1-15.
    doi: 10.1016/j.cveq.2016.11.001google scholar: lookup
  23. Macallister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse-effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202(1):71-77.
  24. Read WK. Renal medullary crest necrosis associated with phenylbutazone therapy in horses. Vet Pathol 1983;20(6):662-669.
  25. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 2004;10(6):577-588.
  26. Vermillion ST, Robinson CJ. Antiprostaglandin drugs. Obstet Gynecol Clin North Am 2005;32(3):501-517.
  27. Renaudin CD, Troedsson MHT, Gillis CL, King VL, Bodena A. Ultrasonographic evaluation of the equine placenta by transrectal and transabdominal approach in the normal pregnant mare. Theriogenology 1997;47(2):559-573.
  28. Renaudin CD, Liu IKM, Troedsson MHT, Schrenzel MD. Transrectal ultrasonographic diagnosis of ascending placentitis in the mare: a report of two cases. Equine Vet Educ 1999;11(2):69-74.
  29. Reef VB, Vaala WE, Worth LT, Sertich PL, Spencer PA. Ultrasonographic assessment of fetal well-being during late gestation: development of an equine biophysical profile. Equine Vet J 1996;28(3):200-208.
  30. McGlothlin JA, Lester GD, Hansen PJ. Alteration in uterine contractility in mares with experimentally induced placentitis. Reproduction 2004;127(1):57-66.
    doi: 10.1530/rep.1.00021google scholar: lookup
  31. Leblanc MM, Mays MBC, Sheerin BR, Hendry JM, O'Donnell LJ. Route of fetal infection in a model of ascending placentitis in the mare. Pferdeheilkunde 2001;17(6):689-689.
  32. Lyle SK. Immunology of infective preterm delivery in the mare. Equine Vet J 2014;46(6):661-668.
    doi: 10.1111/evj.12243google scholar: lookup
  33. Cox S, Villarino N, Sommardahl C. Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen. Vet J 2013;198(2):382-385.
    doi: 10.1016/j.tvjl.2013.07.035google scholar: lookup
  34. Ousey JC, Dudan F, Rossdale PD. Preliminary studies of mammary secretions in the mare to assess fetal readiness for birth. Equine Vet J 1984;16(4):259-263.
  35. Garton NJ, Gilleron M, Brando T. A novel lipoarabinomannan from the equine pathogen Rhodococcus equi - Structure and effect on marcophage cytokine production. J Biol Chem 2002;277(35):31722-31733.
    doi: 10.1074/jbc.m203008200google scholar: lookup
  36. Berghaus LJ, Giguere S, Sturgill TL. Effects of age and macrophage lineage on intracellular survival and cytokine induction after infection with Rhodococcus equi. Vet Immunol Immunopathol 2014;160(1-2):41-50.
    doi: 10.1016/j.vetimm.2014.03.010google scholar: lookup
  37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):45e.
  38. Kim CJ, Romero R, Chaemsaithong P, Kim JS. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol 2015;213(4 Suppl):S53-S69.
    doi: 10.1016/j.ajog.2015.08.041google scholar: lookup
  39. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol 2015;213(4 Suppl):S29-S52.
    doi: 10.1016/j.ajog.2015.08.040google scholar: lookup
  40. Gomez-Lopez N, Romero R, Galaz J. Cellular immune responses in amniotic fluid of women with preterm labor and intra-amniotic infection or intra-amniotic inflammation. Am J Reprod Immunol 2019;82(5):e13171.
    doi: 10.1111/aji.13171google scholar: lookup
  41. Peiris HN, Romero R, Vaswani K. Preterm labor is characterized by a high abundance of amniotic fluid prostaglandins in patients with intra-amniotic infection or sterile intra-amniotic inflammation. J Maternal Fetal Neonatal Med 2019;32:1-16.
    doi: 10.1080/14767058.2019.1702953google scholar: lookup
  42. Loux SC, Fernandes CB, Dini P. Small RNA (sRNA) expression in the chorioallantois, endometrium and serum of mares following experimental induction of placentitis. Reprod Fertil Dev 2019;31(6):1144.
    doi: 10.1071/rd18400google scholar: lookup
  43. McDuffie R Jr, Sherman MP, Gibbs RS. Amniotic fluid tumor necrosis factor-α and interleukin-1 in a rabbit model of bacterially induced preterm pregnancy loss. Am J Obstet Gynecol 1992;167(6):1583-1588.
    doi: 10.1016/0002-9378(92)91745-vgoogle scholar: lookup
  44. Sundrani D, Narang A, Mehendale S, Joshi S, Chavan-Gautam P. Investigating the expression of MMPs and TIMPs in preterm placenta and role of CpG methylation in regulating MMP-9 expression. IUBMB Life 2017;69(12):985-993.
    doi: 10.1002/iub.1687google scholar: lookup
  45. Lannon SM, Vanderhoeven JP, Eschenbach DA, Gravett MG, Adams Waldorf KM. Synergy and interactions among biological pathways leading to preterm premature rupture of membranes. Reprod Sci 2014;21(10):1215-1227.
    doi: 10.1177/1933719114534535google scholar: lookup
  46. Geng J, Huang C, Jiang S. Roles and regulation of the matrix metalloproteinase system in parturition. Mol Reprod Dev 2016;83(4):276-286.
    doi: 10.1002/mrd.22626google scholar: lookup
  47. Tsatas D, Baker MS, Rice GE. Differential expression of proteases in human gestational tissues before, during and after spontaneous-onset labour at term. J Reprod Fertil 1999;116(1):43-49.
  48. Vadillo-Ortega F, Estrada-Gutierrez G. Role of matrix metalloproteinases in preterm labour. BJOG Int J Obstet Gynaecol 2005;112:19-22.
    doi: 10.1111/j.1471-0528.2005.00579.xgoogle scholar: lookup
  49. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274(31):21491-21494.
    doi: 10.1074/jbc.274.31.21491google scholar: lookup
  50. So T, Ito A, Sato T, Mori Y, Hirakawa S. Tumor necrosis factor alpha stimulates the biosynthesis of matrix metalloproteinases and plaminogen-activator in cultured human chorionic cells. Biol Reprod 1992;46(5):772-778.
    doi: 10.1095/biolreprod46.5.772google scholar: lookup
  51. Arechavaleta-Velasco F, Ogando D, Parry S, Vadillo-Ortega F. Production of matrix metalloproteinase-9 in lipopolysaccharide-stimulated human amnion occurs through an autocrine and paracrine proinflammatory cytokine-dependent system. Biol Reprod 2002;67(6):1952-1958.
    doi: 10.1095/biolreprod.102.004721google scholar: lookup
  52. Xu P, Alfaidy N, Challis JRG. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human placenta and fetal membranes in relation to preterm and term labor. J Clin Endocrinol Metab 2002;87(3):1353-1361.
    doi: 10.1210/jc.87.3.1353google scholar: lookup
  53. Cockle JV, Gopichandran N, Walker JJ, Levene MI, Orsi NM. Matrix metalloproteinases and their tissue inhibitors in preterm perinatal complications. Reprod Sci 2007;14(7):629-645.
    doi: 10.1177/1933719107304563google scholar: lookup
  54. Szostek-Mioduchowska AZ, Baclawska A, Okuda K, Skarzynski DJ. Effect of proinflammatory cytokines on endometrial collagen and metallopeptidase expression during the course of equine endometrosis. Cytokine 2019;123:e154767.
    doi: 10.1016/j.cyto.2019.154767google scholar: lookup

Citations

This article has been cited 7 times.
  1. Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses. Animals (Basel) 2023 May 10;13(10).
    doi: 10.3390/ani13101597pubmed: 37238029google scholar: lookup
  2. Hardefeldt L, Thomas K, Page S, Norris J, Browning G, El Hage C, Stewart A, Gilkerson J, Muscatello G, Verwilghen D, van Galen G, Bauquier J, Cuming R, Reynolds B, Whittaker C, Wilkes E, Clulow J, Burden C, Begg L. Antimicrobial prescribing guidelines for horses in Australia. Aust Vet J 2025 Dec;103(12):781-889.
    doi: 10.1111/avj.70003pubmed: 40903020google scholar: lookup
  3. Riley JW, Chance LM, Barshick MR, Johnson SE. Administration of sodium hyaluronate to adult horses prior to and immediately after exercise does not alter the range of motion in either the tarsus or metacarpophalangeal joints. Transl Anim Sci 2024;8:txae153.
    doi: 10.1093/tas/txae153pubmed: 39554613google scholar: lookup
  4. Ignácio FS, Garcia LV, de Souza GG, Amatti LZ, de Barros LD, Bergfelt DR, Camargo GS, de Meira C, de Almeida BFM. Hematological and Biochemical Effects Associated with Prolonged Administration of the NSAID Firocoxib in Adult Healthy Horses. Vet Sci 2024 Jun 5;11(6).
    doi: 10.3390/vetsci11060256pubmed: 38922003google scholar: lookup
  5. Ospina J, Carmona JU, López C. Short-Term Effects of Two COX-2 Selective Non-Steroidal Anti-Inflammatory Drugs on the Release of Growth Factors and Cytokines from Canine Platelet-Rich Gel Supernatants. Gels 2024 Jun 12;10(6).
    doi: 10.3390/gels10060396pubmed: 38920942google scholar: lookup
  6. Morales-Vázquez MM, Meza-Serrano E, Lara-Pereyra I, Acuña-González RJ, Alonso-Morales R, Hayen-Valles S, Boeta AM, Zarco L, Lozano-Cuenca J, López-Canales JS, Flores-Herrera H. Equine Placentitis in Mares Induces the Secretion of Pro-Inflammatory Cytokine eIL-1β and the Active Extracellular Matrix Metalloproteinase (MMP)-9. Vet Sci 2023 Aug 22;10(9).
    doi: 10.3390/vetsci10090532pubmed: 37756054google scholar: lookup
  7. Araújo RA, Sales NAA, Basile RC, Feringer-Junior WH, Apparício M, Ferraz GC, Queiroz-Neto A. Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses. Vet Sci 2023 Aug 22;10(9).
    doi: 10.3390/vetsci10090531pubmed: 37756053google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.